AG
RLAY icon

Algert Global’s Relay Therapeutics RLAY Stock Holding History

Algert Global’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,510
Closed -$483K – 1387
2026
Q1 		$483K Sell
48,510
-97,990
-67% -$877K 0.01% 971
2025
Q4 		$1.24M Sell
146,500
-262,340
-64% -$1.87M 0.02% 806
2025
Q3 		$2.13M Sell
408,840
-593,176
-59% -$2.26M 0.04% 668
2025
Q2 		$3.47M Buy
1,002,016
+70,765
+8% +$210K 0.07% 452
2025
Q1 		$2.44M Sell
931,251
-63,672
-6% -$249K 0.06% 537
2024
Q4 		$4.1M Buy
994,923
+481,646
+94% +$2.62M 0.1% 346
2024
Q3 		$3.63M Buy
513,277
+36,389
+8% +$272K 0.1% 359
2024
Q2 		$3.11M Buy
476,888
+174,953
+58% +$1.2M 0.1% 321
2024
Q1 		$2.51M Buy
301,935
+69,794
+30% +$681K 0.1% 341
2023
Q4 		$2.56M Buy
232,141
+31,318
+16% +$264K 0.1% 332
2023
Q3 		$1.69M Buy
200,823
+76,573
+62% +$823K 0.08% 418
2023
Q2 		$1.56M Buy
124,250
+90,039
+263% +$1.12M 0.07% 480
2023
Q1 		$563K Sell
34,211
-41,480
-55% -$744K 0.03% 793
2022
Q4 		$1.13M Buy
+75,691
New +$1.45M 0.06% 522

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Algert Global's RLAY Position: Q2 2026 in Review

Algert Global sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 48,510 shares — an estimated $483K sold.

Algert Global first reported a position in RLAY in Q4 2022 and held it in 14 quarters. The position peaked at $4.1M in Q4 2024. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Algert Global reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 48,510 Relay Therapeutics shares in Q2 2026, an estimated $483K.
  • Algert Global first reported a position in Relay Therapeutics in Q4 2022 and held it in 14 quarters.
  • Algert Global's Relay Therapeutics position peaked at $4.1M in Q4 2024.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.